NCT01806571View on ClinicalTrials.gov

Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 12, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

November 30, 2019

Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
DRUG

Cytarabine

Given IV

DRUG

Daunorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nilotinib

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER